Acrivon Therapeutics annual stock-based compensation
2021
2022
2023
2024
2025
Acrivon Therapeutics Stock-Based Compensation Growth & History (ACRV)
Acrivon Therapeutics's stock-based compensation was $14.7M for fiscal 2025.
View full Acrivon Therapeutics company overviewAcrivon Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.7M | $432,000 | +3.02% |
| 2024 | 2024-12-31 | $14.3M | $2.7M | +22.98% |
| 2023 | 2023-12-31 | $11.6M | $9.4M | +431.72% |
| 2022 | 2022-12-31 | $2.2M | $1.7M | +339.64% |
| 2021 | 2021-12-31 | $497,000 | — | — |
Acrivon Therapeutics quarterly stock-based compensation
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.2M | −$1.7M | −43.62% |
| Q1 2026 | 2026-03-31 | $2.2M | −$1.6M | −42.47% |
| Q4 2025 | 2025-12-31 | $3.1M | −$616,000 | −16.62% |
| Q3 2025 | 2025-09-30 | $3.9M | $240,000 | +6.54% |
| Q2 2025 | 2025-06-30 | $3.9M | $361,000 | +10.12% |
| Q1 2025 | 2025-03-31 | $3.8M | $447,000 | +13.37% |
| Q4 2024 | 2024-12-31 | $3.7M | $649,000 | +21.22% |
| Q3 2024 | 2024-09-30 | $3.7M | $443,000 | +13.72% |
| Q2 2024 | 2024-06-30 | $3.6M | $880,000 | +32.76% |
| Q1 2024 | 2024-03-31 | $3.3M | $698,000 | +26.38% |
| Q4 2023 | 2023-12-31 | $3.1M | $1.4M | +85.90% |
| Q3 2023 | 2023-09-30 | $3.2M | $3.0M | +1108.99% |
| Q2 2023 | 2023-06-30 | $2.7M | $2.5M | +1052.79% |
| Q1 2023 | 2023-03-31 | $2.6M | $2.6M | +6515.00% |
| Q4 2022 | 2022-12-31 | $1.6M | — | — |
| Q3 2022 | 2022-09-30 | $267,000 | $240,000 | +888.89% |
| Q2 2022 | 2022-06-30 | $233,000 | — | — |
| Q1 2022 | 2022-03-31 | $40,000 | — | — |
| Q3 2021 | 2021-09-30 | $27,000 | — | — |
Acrivon Therapeutics stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Acrivon Therapeutics's stock-based compensation increased from $497,000 to $14.7M, a change of $14.2M. The latest reported quarter, Q2 2026, shows $2.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acrivon Therapeutics source filings ↗